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Objectives: We compared the efﬁcacy of paracetamol/controlled-release (CR) oxycodone and para-
cetamol/naproxen for treatment of acute postoperative pain at home after ambulatory surgery.
Secondary outcomes were adverse effects of study medication, treatment satisfaction, and postoperative
analgesic compliance.
Methods: Patients undergoing ambulatory knee arthroscopy or inguinal hernia repair surgery (n ¼ 105)
were randomized into 3 groups: Group1 paracetamol/naproxen (n ¼ 35), Group 2 paracetamol/CR
oxycodone for 24 hours (n ¼ 35), and Group 3 paracetamol/CR oxycodone for 48 hours (n ¼ 35). Pain
intensity at movement and at rest using a visual analog scale as well as satisfaction with postoperative
analgesia and side effects were recorded for up to 48 hours postoperatively. Compliance with study
medication was also assessed.
Results: For pain at movement and at rest, no signiﬁcant differences were found between the
paracetamol/naproxen group and either the paracetamol/CR oxycodone for 24 hours group (β ¼ 2.6
[4.9]; P ¼ 0.597) or the paracetamol/CR oxycodone for 48 hours (β ¼ –1.7 [5.1]; P ¼ 0.736). No major
adverse effects of study medication were registered and satisfaction with postoperative pain treatment
was high in all groups. Compliance was comparable across the groups. Despite clear instructions,
8 patients with the lowest pain scores did not use any of the prescribed pain medication.
Conclusions: Paracetamol/CR oxycodone and paracetamol/naproxen are equally effective in treatment of
acute postoperative pain at home after ambulatory surgery with comparable patient satisfaction level.
We suggest paracetamol/CR oxycodone to be a valuable alternative for the current paracetamol/naproxen
gold standard, particularly in patients with a contraindication for nonsteroidal anti-inﬂammatory drugs.
ClinicalTrials.gov identiﬁer: NCT02152592.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Adequate postoperative pain management is an essential part
of perioperative care because postoperative pain results in patient
discomfort and may decrease patient satisfaction.1 More impor-
tant, insufﬁcient postoperative pain therapy is associated with anInc. This is an open access article u
epartment of Anesthesiology
sse Campus, Stadsomvaart 11,
sel).increase in perioperative morbidity and mortality and is an
important risk factor for the development of chronic postsurgical
pain.2–4 It is also a common cause of delayed discharge and
unanticipated hospital admission in outpatients.5–7 In particular,
patients who undergo abdominal operations (including inguinal
hernia repair surgery), orthopedic surgery (including knee arthro-
scopy), or breast surgery seem to be at the highest risk for
developing severe pain after day surgery.8
In the ambulatory setting, a multimodal approach to pain
control combining intraoperative opioids, paracetamol, nonsteroi-
dal anti-inﬂammatory drugs (NSAIDs), weak opioids, and local andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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often administered in the inpatient and chronic pain setting.
However, strong opioids in the home setting after ambulatory
surgery have rarely been studied because of fear for hazardous
adverse effects such as respiratory depression.11
Paracetamol in combination with naproxen, an NSAID with a
favorable adverse-effect proﬁle,12 comprise the standard multi-
modal pain treatment model at Maastricht University Medical
Centerþ for patients at home after ambulatory surgery. Never-
theless, NSAIDs are not always sufﬁciently effective,13 have numer-
ous contraindications, and consequently are not suitable in up to
25% of all patients.14 Postoperative analgesic habits in the inpatient
setting and the World Health Organization analgesic ladder
suggest that strong opioids are more effective than NSAIDs and
might therefore be an alternative. Oxycodone is a strong opioid
that was used for the ﬁrst time in Germany in 191715 and may
display signiﬁcant afﬁnity to both m-opioid and κ-opioid recep-
tors.16 In contrast to morphine, oxycodone possesses high oral
bioavailability with less interindividual variation. As a result, the
plasma concentrations following oral administration of oxycodone
are far more predictable than after morphine.17 Other beneﬁcial
characteristics of oxycodone are related to the lower incidence of
adverse effects,18 a rapid onset of action18,19 and an absence of a
ceiling dose.19 Compared with immediate-release oxycodone,
controlled-release (CR) oxycodone has the advantage of maintain-
ing a therapeutic concentration for a more prolonged period,
which may avoid peak-and-trough plasma concentrations and
thus provide sustained pain relief with fewer side effects such as
nausea and vomiting.20–22 The primary objective of our study was
to assess and compare the efﬁcacy of paracetamol/CR oxycodone
for 1 or 2 days and our current pain protocol (ie, paracetamol/
naproxen) in the treatment of acute postoperative pain at home
after painful day-case surgery. We hypothesized that ambulatory
patients postoperatively treated with paracetamol/CR oxycodone
for 1 or 2 days would achieve better pain relief at movement
compared to patients treated with paracetamol/naproxen. The
second goal was to assess adverse effects of study medication,
treatment satisfaction, and patients’ analgesic adherence in the
outpatient setting.Materials and Methods
After obtaining approval from the Medical Ethics Committee of
Maastricht University Medical Centerþ and written informed
consent, 105 patients scheduled for painful ambulatory surgery
(ie, knee arthroscopy and unilateral open or laparoscopic inguinal
hernia repair) were enrolled in an open randomized controlled
trial (RCT) at our preassessment clinic. This trial was carried out in
accordance with The Code of Ethics of the World Medical Associ-
ation (Declaration of Helsinki) for experiments involving human
beings.
Eligible patients were aged 18 to 70 years and had American
Society of Anesthesiologists (ASA) physical status I or II. Exclusion
criteria were cognitive impairment, preoperative pharmacologic
pain treatment, allergy to or a contraindication for taking the
study medication (eg, paracetamol, oxycodone, naproxen, or
another NSAID), porphyria, pregnancy, lactation, history of severe
renal, hepatic, pulmonary, or cardiac failure, current symptoms or
history of gastrointestinal bleeding, ileus, chronic obstipation,
history of substance abuse, or use of medication with a suppressive
effect on the central nervous system. Dropout criteria were
surgical complications leading to either resurgery or unanticipated
hospital admission. Patients were enrolled by a study nurse,
consecutively included, and randomized using a computer-
generated list. Three study groups were included, of which theﬁrst group served as control group and the second and third as
intervention groups: Group 1 paracetamol/naproxen (PCM/NAPR),
where patients were assigned to postoperative analgesia using
naproxen 500 mg orally BID for 48 hours postoperatively (n ¼ 35);
Group 2 paracetamol/CR oxycodone for 24 hours (PCM/Oxy24h),
where patients received CR oxycodone 10 mg orally BID for
24 hours (n ¼ 35); and Group 3 paracetamol/CR oxycodone for
48 hours (PCM/Oxy48h), where patients were postoperatively
treated with CR oxycodone 10 mg orally BID for 48 hours
(n¼35). All patients also received paracetamol 1000 mg 4 times
a day for 48 hours postoperatively and were ordered to take their
analgesics according to a ﬁxed-dose schedule to prevent rather
than to cure pain. To obtain approval from our Medical Ethics
Committee, naproxen as rescue medication was obligatory for
patients in Groups 2 and 3. Because of organizational difﬁculties,
this RCT could not be made double-blind. Upon hospital admission,
patients received a pain diary, a stamped addressed envelope, and
instructions for use. Patients were asked to provide a detailed
medical history and demographic information, including age, sex,
body mass index, ASA classiﬁcation, and history of postoperative
nausea and vomiting (PONV). Furthermore, baseline preoperative
pain measurement using a numeric rating scale (0–100) was
assessed verbally. Thirty minutes before surgery, premedication
with oral paracetamol 1000 mg was given to all patients. Type and
duration of surgery and anesthesia were registered. Appropriate
type of anesthesia and antiemetic therapy was chosen by the
attending anesthesiologist. Postoperative pain at movement and at
rest was measured by a visual analog scale (VAS) (0–100). PONV,
pruritus, urine retention, pyrosis, cardiorespiratory complaints,
abdominal complaints, and bleeding were assessed in the post-
anesthetic care unit (PACU) and in the surgical holding area before
discharge. Acute postoperative pain (VAS Z40) in the PACU was
treated with subsequent bolus injections of piritramide 0.1 mg/kg
intravenously until pain relief was satisfactory. Before hospital
discharge, patients received the study medication and instructions
for use.
Recovery after discharge was assessed using a diary for up to
48 hours after surgery. Three times a day, patients rated pain at
movement and at rest (using a 0–100 VAS), fatigue, PONV,
pruritus, micturition problems, pyrosis, constipation, and abdomi-
nal complaints. Overall satisfaction with postoperative analgesia
was assessed (0 ¼ not satisﬁed at all and 10 ¼ very satisﬁed), and
patients were also asked whether they had contacted a general
practitioner or hospital postoperatively. Furthermore, compliance
with prescribed analgesia was assessed 3 times a day by checking
whether patients used the study medication as prescribed and the
use of other pain medication. Analgesic compliance was subdi-
vided in 3 categories: always ¼ full compliance, sometimes ¼
partial compliance, and never ¼ no compliance.
Statistical analysis
The statistical power analysis was based on a calculation using
an SD of 22 for the postoperative VAS scores. To detect a difference
of 15 with a power of 0.80 and α ¼ 0.05, 35 patients in each group
were required. Baseline data and secondary outcomes were
analyzed using the Student t test for parametric data, the Mann-
Whitney U test for nonparametric pain scores, and the χ2 test for
categorical data. Missing baseline values (ASA and preoperative
pain) were imputed. Multivariate analysis of the primary outcome,
VAS scores of postoperative pain at movement and rest, was
performed using a random intercept model with autoregressive
covariance structure. For multivariate analysis the following cova-
riables were assessed: baseline pain (numeric rating scale), age,
sex, body mass index, ASA classiﬁcation, type of surgery, duration
of surgery, type of anesthesia, and pain (VAS) at PACU, holding, and
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versus the PCM/Oxy24h group and the PCM/Oxy48h group as a
function of time were assessed with the PCM/Oxy24h treatment
and PCM/Oxy48h treatment, and time ﬁxed effects. Regression
coefﬁcients (β) and SD are presented and reﬂect the change in pain
for each unit of change in the predictor. The data were analyzed
according to the intention to treat principle. All analyses were
performed using the Statistical Package for the Social Sciences
(version 18, IBM-SPSS Inc, Armonk, New York). A P value o0.05
was considered statistically signiﬁcant.Results
A ﬂow chart of patient selection and drop out is presented in
Figure 1. Four patients were hospitalized, but not as a result of
surgical complications. Patients included underwent surgery
between October 2007 and March 2009. Fifty-nine patients
received spinal anesthesia with either hyperbaric bupivacine
0.5% (10–15 mg) or plain lidocaine 2% (60–80 mg). In 3 cases,
spinal anesthesia was converted to general anesthesia. Forty-sixEnrollment
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Figure 1. Study ﬂow chart. Analysis according to intention-to-treat principle. PCM/NAP
PCM/Oxy48h ¼ paracetamol/oxycodone for 48 hours.patients received general anesthesia. Anesthesia was generally
induced with propofol (1.5–2 mg/kg IV) and sufentanil (0.1–0.3
μg/kg). After a laryngeal mask airway was inserted, anesthesia was
maintained with sevoﬂurane. Wound inﬁltration with local anes-
thesia was performed in 15 patients (Table I). Postoperatively,
10 patients who underwent general anesthesia received piritra-
mide (Table I). With regard to baseline and surgery characteristics,
there were no statistically signiﬁcant differences between the
PCM/NAPR group and the 2 PCM/Oxy groups (Table I).
For pain at movement, no signiﬁcant difference was found
between the PCM/NAPR group and either the PCM/Oxy24h group
(β ¼ 2.6 [4.9]; P ¼ 0.598) or the PCM/Oxy48h group (β ¼ –1.7
[5.1]; P ¼ 0.737) (Figure 2). Time course (with decrease in pain
over time [hours]) (β ¼ –0.4 [0.03]; P o 0.001) and acute
postoperative pain (VAS Z40) directly measured at the PACU
was a signiﬁcant risk factor (β ¼ 0.3 [0.09]; P ¼ 0.004) for pain at
movement. In addition, there was an increased risk for pain at
movement in patients who underwent inguinal hernia repair
compared with arthroscopy (β ¼ 9.2 [4.9]; P ¼ 0.064). For pain
at rest, no signiﬁcant difference between the study groups and
control group was found. Besides a signiﬁcant decrease in pain-up (pain diary not
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Table I
Baseline and perioperative characteristics.*
Characteristic PCM/NAPR
(n ¼ 35)
PCM/Oxy24h
(n ¼ 35)
PCM/Oxy48
(n ¼ 35)
Age, y 45.4 (14.2) 45.1 (14.2) 48.5 (10.2)
Sex male/female 24/11 26/9 27/8
Body mass index 25.6 (3.3) 25.7 (3.8) 26.0 (3.0)
American Society of
Anesthesiologists classiﬁcation
I/II
29/6 24/11 26/9
Pain baseline† 3.6 (0–22.8) 3.0 (0–13.2) 5.0 (0–30.0)
Surgery
Laparoscopic inguinal hernia
repair
6 6 5
Open inguinal hernia repair 2 2 3
Arthroscopy‡ 27 27 27
Duration of surgery, min 46 (14) 50 (21) 47 (17)
Anesthesia
General/ þ local 11/þ 5 17/þ 1 8/þ 4
Spinal/ þ local 16/þ 1 15/þ 2 20/þ 2
Conversion spinal to general 2 0 1
Piritramide postoperative
PACU IV 5 7 2
PACU IM 0 0 2
PACU IV þ IM 0 1 0
Holding IM 0 2 0
IM ¼ intramuscular; IV ¼ intravenous; PACU ¼ postanesthetic care unit.
n Values are presented as number, mean (SD), or median (interquartile range).
† Based on numerical rating scale of 0 to 100.
‡ Anterior cruciate ligament reconstruction surgery was not included.
Table II
Complications on Postoperative Days 1 and 2.*
Complication PCM/
NAPR
PCM/
Oxy24h
PCM/
Oxy48h
Fatigue 23 (66) 19 (54) 25 (71)
Nausea 5 (14) 7 (20) 8 (23)
Vomit 0 (0) 0 (0) 1 (3)
Micturition problems 0 (0) 0 (0) 1 (3)
Constipation 12 (34) 4 (11)† 11 (31)
Pyrosis 3 (9) 3 (9) 1 (3)
Abdominal complaints 5 (14) 7 (20) 4 (11)
Pruritus 7 (20) 3 (9) 8 (23)
Contact general practitioner or
hospital
3 (9) 0 (0) 0 (0)
PCM/NAPR ¼ paracetamol/naproxen; PCM/Oxy24h ¼ paracetamol/oxycodone for
24 hours; PCM/Oxy48h ¼ paracetamol/oxycodone for 48 hours.
n Number (%) of patients reporting complications.
† P ¼ 0.041 compared with PCM/NAPR group.
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body mass index as a signiﬁcant risk factor for pain at rest. None of
the other covariables, including type of anesthesia (general vs
spinal), had a signiﬁcant effect on either pain at movement or pain
at rest.
Numbers of self-reported complications were comparable for
all groups, except for constipation that was reported to a signiﬁ-
cantly less degree in the PCM/Oxy24h group compared with the
PCM/NAPR group (Table II). No life-threatening respiratory
depressions or other major adverse effects of study medication
were reported. Satisfaction with postoperative pain treatment was100
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Figure 2. Pain at movement on Postoperative Days 1 and 2. Median (interquartile
range), based on visual analog scale rating (0–100). PCM/NAPR ¼ paracetamol/
naproxen; PCM/OXY1 ¼ paracetamol/oxycodone for 24 hours; PCM/OXY2 ¼
paracetamol/oxycodone for 48 hours.high: mean (SD [range]) 8.3 (1.7 [4–10]), 8.1 (1.5 [4–10]), and 8.6
(1.1 [6–10]) for the PCM/NAPR, PCM/Oxy24h, and PCM/Oxy48h
group, respectively. Use of rescue medication was reported by only
3 patients, all of whom were in the PCM/Oxy24h group. Three
patients in the PCM/NAPR group used unprescribed extra pain
medication.
Compliance was similar across groups. Despite clear instructions
during the informed consent procedure and before discharge,
8 patients did not use any of the prescribed pain medication. When
associated with their postoperative pain scores, it appeared that
these 8 patients did not experience postoperative pain (Table III).Discussion
A multimodal analgesic regimen consisting of paracetamol/CR
oxycodone for either 24 or 48 hours immediately after surgery was
found to be equally effective in reducing postoperative pain
compared with paracetamol/naproxen in an adult population
undergoing ambulatory knee arthroscopy or inguinal hernia repair
surgery. No respiratory depressions or other major adverse effects
of study medication were reported, and the incidence of opioid-
related adverse effects like PONV was comparable in the 3 groups.
Overall satisfaction with postoperative analgesia was high across
all 3 groups. Although the analgesic efﬁcacy and safety of oral
oxycodone at home after surgery has already been conﬁrmed in
1 study,23 ours is the ﬁrst RCT to demonstrate equipotent analgesic
efﬁcacy of a combination of paracetamol and CR oxycodone with
our standard multimodal pain management at home after day
surgery; that is, paracetamol with a NSAID. Paracetamol/CR oxy-
codone seems to be a valuable alternative to paracetamol/nap-
roxen, in particular for those patients with a contraindication for
NSAIDs, which occurs in up to 25% of all patients.14Table III
Compliance and maximum pain scores on Postoperative Days 1 and 2 in relation to
compliance.*
Compliance PCM/NAPR PCM/Oxy24h PCM/Oxy48h
Full compliance N/max VAS*† 17/96 19/81 22/76
Partial compliance N/max VAS 13/77 11/93 8/79
No compliance N/max VAS 3/2 2/20 3/7
Missing N 2 3 2
N ¼ number; VAS ¼ visual analog scale.
n Medication use as prescribed: always ¼ full compliance, sometimes ¼ partial
compliance, never ¼ no compliance.
† Pain at movement, maximum score per group (VAS of 0–100).
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known.24 In particular, CR oxycodone seems to possess an excel-
lent proﬁle for postoperative pain relief characterized by produc-
ing a relatively constant serum opioid level with sustained pain
relief and fewer side effects.20,22 Two studies have compared
intravenous patient-controlled analgesia with an opioid, a gold
standard for the management of pain after major surgery, with
oral CR oxycodone after major surgery in an inpatient setting.21,22
Both studies demonstrated a similar level of pain relief in the
2 study groups with a lower incidence of PONV in the CR
oxycodone group and without occurrence of any serious adverse
event. They concluded that oral CR oxycodone is a less expensive,
more convenient, and safe analgesic alternative compared with
intravenous patient-controlled analgesia with an opioid. In 3 other
studies, oral CR oxycodone was compared with epidural analgesia
to reduce postoperative pain.25–27 These studies also found pain
relief to be satisfactory in both study groups, with a similar
incidence of PONV and without occurrence of serious adverse
effects. High patient satisfaction with oral CR oxycodone after
laparoscopic hysterectomy is also conﬁrmed.28
Although one could presume a higher incidence of opioid-
related adverse effects in the 2 CR oxycodone groups, no differ-
ences in adverse effects between the 3 study groups were found.
However, our study was not powered a priori to detect signiﬁcant
differences in the incidence of adverse effects. Nonetheless, our
data are consistent with previous studies. In an RCT comparing the
effect of oral ibuprofen and celecoxib in preventing pain after
ambulatory surgery with placebo, White et al29 could not detect
any difference in incidence of PONV despite the use of 2 times
more rescue opioid analgesic medication in the placebo group.
Another study also failed to detect signiﬁcant differences in post-
operative side effects between ibuprofen and paracetamol plus
codeine, except for signiﬁcantly more constipation in the second
group.30 Furthermore, several investigators have demonstrated a
reduced incidence of side effects of CR oxycodone compared with
other opioids.20–22 Finally, pain itself has been associated with
nausea and other opioid-related adverse effects, and effective
treatment of pain can diminish nausea.31
One of our secondary outcomes was compliance with post-
operative pain medication. The literature reports that noncompli-
ance by chronic pain patients using analgesia is a frequent and
well-known problem.32,33 However, to our knowledge, this is the
ﬁrst study to investigate compliance of patients to acute post-
operative pain medication. Our study shows that analgesic adher-
ence is related to postoperative pain after ambulatory surgery,
independent of the type of pain medication (ie, NSAIDs or opioids).
Although we cannot prove a causal relation, patients with little or
no pain are obviously not triggered by a pain stimulus to take their
pain medication. Our observations are supported by ﬁndings from
studies on patients with chronic pain. Two large studies demon-
strated that higher levels of pain correspond to more regular
analgesic use.34,35 In contrast, a cross-sectional clinical survey in
1407 patients with chronic noncancer pain pointed out that there
is a small but signiﬁcant inverse relationship between analgesic
adherence and pain intensity.36 Future studies are needed to clear
up this inconsistency.
There are several limitations to our study. First, because of
organizational difﬁculties, this RCT was not double-blind. There-
fore, there is potential risk for information bias. Second, secondary
end points (ie, adverse effects of pain medication, patient sat-
isfaction, and compliance) did not reach statistical signiﬁcance,
except for constipation. However, it should be emphasized that our
study was not powered for secondary outcomes. Third, prescrip-
tion of rescue medication was only provided in the 2 CR oxycodone
groups. Moreover, rescue medication consisted of naproxen. Evi-
dently, this anomaly carries great risk for overestimation of theefﬁcacy of pain relief in the 2 CR oxycodone groups. Nevertheless
use of rescue medication was reported by only 3 patients, all of
them in the PCM/Oxy24h group. Also 3 patients in the PCM/NAPR
group used extra pain medication. Fourth, anesthesia during
surgery was not standardized. Obviously, there is a potential
hazard for treatment bias due to possible differences in amounts
of analgesic and antiemetic drugs used intraoperatively. Never-
theless, distribution of spinal versus general anesthesia over the
3 study groups was identical. Furthermore, all patients received
additional intravenous piritramide in the PACU until satisfactory
pain relief was reached.Conclusions
Paracetamol and CR oxycodone for 24 or 48 hours were both
clinically equivalent to the current paracetamol/naproxen gold
standard in multimodal pain treatment for patients at home after
ambulatory surgery (ie, paracetamol and naproxen). Therefore,
treatment with paracetamol and CR oxycodone is a valuable
alternative to paracetamol and naproxen, particularly in patients
with a contraindication for NSAIDs.Acknowledgments
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